Arbutus Biopharma Corp expected to post a loss of 5 cents a share - Earnings Preview

Arbutus Biopharma

28/07/2025 12:50

Arbutus Biopharma Corp ABUS.OQ ABUS.O is expected to  show a fall in quarterly revenue when it reports  results on July 30 (estimated) for the period ending June 30 2025

The Warminster Pennsylvania-based  company is expected to report a 7.9% decrease in revenue to $1.59 million from $1.73 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Arbutus Biopharma Corp is for a loss of 5 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Arbutus Biopharma Corp is $5.00, about 35.6% above its last closing price of $3.22

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.10
-0.10
-0.13
Missed
-25.7
Dec. 31 2025
-0.08
-0.07
Beat
12.5
Sep. 30 2024
-0.09
-0.09
-0.09
Met
4.9​
Jun. 30 2024
-0.09
-0.10
-0.11
Missed
-13.6
​​Mar. 31 2024
-0.11
-0.11
-0.10
Beat
9.1
Dec. 31 2023
-0.12
-0.12
-0.12
Met
-1.7​
Sep. 30 2023
-0.11
-0.11
-0.12
Missed
-5.4
Jun. 30 2023
-0.11
-0.11
-0.10
Beat
10.9

This summary was machine generated July 28 at 11:50 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)